

Claims:

1. Use of an anti-FcRn antibody or antigen binding fragment thereof for the manufacture of a medicament for the treatment of immune (idiopathic) thrombocytopenic purpura (ITP), wherein the medicament is to be administered subcutaneously, in the range of 1 to 5
5 doses of the antibody over a treatment period of 1 to 12 weeks, wherein the aggregate dose in the treatment period is in the range of 1 to 30 mg per kg, and wherein the anti-FcRn antibody comprises a heavy chain variable domain sequence having the sequence given in SEQ ID NO:29 and a light chain variable domain sequence comprising the sequence given in SEQ ID NO:15.
- 10 2. The use according to claim 1, wherein the antibody is a full length antibody.
3. The use according to claim 2, wherein the full length antibody is selected from the group consisting of an IgG1, IgG4 and IgG4P.
4. The use according to claim 2 or claim 3, wherein the anti-FcRn antibody has a heavy
15 chain comprising the sequence given in SEQ ID NO:72 or SEQ ID NO:87 or SEQ ID NO:43 and a light chain comprising the sequence given in SEQ ID NO:22.
5. The use according to claim 2, 3 or 4, wherein the anti-FcRn antibody is rozanolixizumab.
6. The use according to any one of claims 1 to 5, wherein the antibody or antigen binding fragment is provided as a pharmaceutical composition comprising one or more of a pharmaceutically acceptable excipient, diluent or carrier.
- 20 7. The use according to claim 6, wherein the pharmaceutical composition further comprises one or more other active ingredients.
8. The use according to any one of claims 1 to 7, wherein the treatment is period is 1, 2, 3, 4, 5, 6, 7 or 8 weeks.
9. The use according to claim 8, wherein the treatment is period is 1, 2, 3, 4 or 5 weeks.
- 25 10. The use according to any one of claims 1 to 9, wherein 1, 2, 3, 4 or 5 doses of antibody or binding fragment are to be administered and each dose is in the range of 4mg/kg to 30 mg/kg.
11. The use according to claim 10, wherein each dose is 4mg/Kg, for example to be administered as five individual doses, in particular over a treatment period of five weeks,
30 in particular five consecutive weeks.
12. The use according to claim 10, wherein each dose is 7mg/Kg, for example to be administered as three individual doses, in particular over a treatment period of three weeks, in particular three consecutive weeks.
13. The use according to claim 10, wherein each dose is 10mg/Kg, for example to be
35 administered as two individual doses, in particular over a treatment period of two weeks, in particular two consecutive weeks.
14. The use according to claim 10, wherein a single dose is to be administered.
15. The use according to claim 14 wherein the dose is 15mg/Kg.
16. The use according to claim 14, wherein the dose is 20mg/Kg.
- 40 17. The use according to claim 14, wherein the dose is 25mg/Kg.

18. The use according to claim 14, wherein the dose is 30mg/Kg.
19. The use according to any one of claims 1 to 18 wherein the aggregate dose is selected from 10, 15, 20, 21, 25 and 30 mg/Kg.
20. The use according to any one of claims 1 to 20 wherein the anti-FcRn antibody or
5 antigen binding fragment thereof blocks binding of human IgG to human FcRn.
21. The use according to any one of claims 1 to 21 wherein the anti-FcRn antibody or antigen binding fragment thereof does not bind β 2 microglobulin.
22. The use according to any one of claims 1 to 22 wherein the medicament is to be further administered one or more additional doses that are lower than the initial dose.

10